Last reviewed · How we verify
rTSST-1 Variant Candidate Vaccine
At a glance
| Generic name | rTSST-1 Variant Candidate Vaccine |
|---|---|
| Sponsor | Biomedizinische Forschungs gmbH |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults (PHASE2)
- Amendment of rTSST-1 Variant Vaccine Phase 1 Clinical Trial (PHASE1)
- rTSST-1 Variant Vaccine Phase 1 First-in-man Trail (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rTSST-1 Variant Candidate Vaccine CI brief — competitive landscape report
- rTSST-1 Variant Candidate Vaccine updates RSS · CI watch RSS
- Biomedizinische Forschungs gmbH portfolio CI